Home › Employers › Center for Breakthrough Medicines Holdings, LLC
Center for Breakthrough Medicines Holdings, LLC: H-1B salaries and sponsorship
Center for Breakthrough Medicines Holdings, LLC filed 3 labor condition applications for H-1B and related visas in fiscal years 2023–2026; certified: 2. Median offered salary: $59,426.
Does Center for Breakthrough Medicines Holdings, LLC sponsor H-1B visas?
Center for Breakthrough Medicines Holdings, LLC filed 3 labor condition applications in fiscal years 2023–2026, the latest submitted on May 16, 2025. An LCA is the first step of an H-1B petition, so the employer has sponsored or prepared to sponsor H-1B workers; it does not guarantee sponsorship for any particular job. Check the employer's own job listings.
Salaries by job title
| Job title | LCAs | Median salary |
|---|---|---|
| Director of Microbiology | 2 | $73,070 |
| Associate Scientist | 1 | $45,781 |
Applications by fiscal year
| Fiscal year | LCAs | Median salary |
|---|---|---|
| FY2024 | 2 | $73,070 |
| FY2025 | 1 | $45,781 |
Prevailing wage levels
The Department of Labor sets four prevailing wage levels for each occupation and area, from Level I (entry) to Level IV (fully competent). The employer picks the level that matches the job's requirements.
Where the jobs are
Occupations
Latest applications
| Job title | Base salary | Location | Submitted | Start date | Status |
|---|---|---|---|---|---|
| Associate Scientist | $45,781–$69,952 Level I | King of Prussia, PA | May 16, 2025 | Oct 1, 2025 | Certified |
| Director of Microbiology | $73,070–$225,000 Level III | King of Prussia, PA | Nov 15, 2023 | Feb 15, 2024 | Certified |
| Director of Microbiology | — Level III | King of Prussia, PA | Nov 13, 2023 | Feb 15, 2024 | Denied |
Salaries are the lower end of the wage offered on each application, converted to a yearly amount; statistics use certified full-time applications only. An LCA is not a visa approval and one LCA can cover several positions. Source: U.S. Department of Labor, OFLC LCA Disclosure Data, fiscal years 2023–2026 (latest decision Jun 30, 2026).